Recruiting Volunteers for Specific Studies with Specific Needs, Illnesses, or Treatments

EVEREST II Trial: A prospective, randomized, multi-center phase II IDE clinical study to evaluate percutaneous mitral valve repair system in the treatment of patients with moderate to severe or severe mitral regurgitation (MR). The Evalve Percutaneous Mitral Repair (PMR) system is used by interventional cardiologists and is intended to reduce MR, the leakage of blood backward through the mitral valve each time the left ventricle contracts, adapting the open surgical edge-to-edge technique in a less invasive catheter-based procedure. For more information, contact Aracely Norales RN, FPN, CCRP at (516)562-6904 or Aracely.Norales@chsli.org.

ACT 1 Trial: Asymptomatic Carotid Stenosis, Stenting Versus Endarterectomy Trial, is a randomized trial designed to demonstrate the equivalence (non-inferiority) of carotid artery stenting CAS using the Xact RX Carotid Stent System with the Emboshield Cerebral Protection System compared to carotid endarterectomy (CEA) for the treatment of asymptomatic carotid occlusive disease. The randomization employs a 3:1 ratio of Carotid Artery Stenting versus Carotid Endarterectomy, and subjects will be followed at 30 days, six months and annually for five years.

CHOICE: Carotid Stenting for High Surgical-Risk Patients: Evaluating Outcomes through the Collection of Clinical Evidence Trial will provide additional information regarding the commercially available Abbott Vascular Carotid Stent Systems and Embolic Protection Systems. These approved devices are FDA cleared for use by a wide range of physicians under commercial use conditions. An ongoing post-market surveillance will collect information for 30 days post stent procedure. CHOICE is a non-randomized trial and your doctor may ask you to take part if you meet the high risk criteria in order to treat Carotid Artery Stenosis. If you are interested in these studies, please contact Elizabeth Haag, RN, CCRP at (516) 562-6790 or Elizabeth.Haag@chsli.org

DETERMINE: Enrollment for the DETERMINE study will begin during the summer of 2007. This study will examine the use of Internal Cardioverter Defibrillator (ICD) therapy in patients with a history of coronary artery disease and mild to moderate left ventricular dysfunction

IMPEDE: A non-randomized, longitudinal study designed to determine if intrathoracic impedance is associated with biological and clinical markers of heart failure in patients receiving cardiac resynchronization therapy (CRT). If you are interested in participating in these studies, please contact Regine Bernstein at (516) 562-6662 or Regine.Bernstein@chsli.org.

RESTORE-IT Trial: A consensus opinion is that atherosclerosis is largely a chronic vascular inflammatory disease. The discovery of bacteria within atherosclerotic lesions has generated research into the potential role played by these infectious agents in the disease process. The RESTORE-IT Trial will evaluate the effectiveness of an investigational antibiotic on existing carotid arterial plaque disease progression as measured by serial Carotid Sonograms and Carotid MRI. For additional information please contact Jeannette McLaughlin RN, CCRP at (516) 562-6788 or Jeannette.McLaughlin@chsli.org

Interested in Participating or would like more information? Send an email to researchvolunteer@chsli.org with "St. Francis Hospital Clinical Trial Participation" in the Subject line. St. Francis Hospital strictly adheres to HIPAA regulations for protection of privacy. Include the following information:

• Name:
• Address:
• Daytime phone:
• Work phone:
• Email:

An associate from our research department will contact you. All information submitted will be maintained confidentially and will be used for the sole purpose of recruitment for research studies

Click here for Frequently Asked Questions for Research Trial Participation (adapted from Clinicaltrials.gov)